关于停药的相关内容

摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
$ `2 k) o* _; P7 p: g$ C    关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。
) |3 U4 y( @% L/ x: {
# v8 R! H0 l2 ~4 |; P, g, Y作者：来自澳大利亚
来源：Haematologica. 2011.8.9.
Dear Group,
/ f- }2 Z: W/ Y4 c8 `
Some of you are on Dasatinib (Sprycel) and we wish to give news on all CML
5 ^) A" w5 P9 x* ctherapies. Here is a report from Australia on 3 patients who went off Sprycel
; `/ z' ^) C' j- ~$ Q( safter stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
remain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
: r) i6 M# j3 T* Hdoes spike up the immune system so I hope more reports come out on this issue.
5 F1 z4 z6 T5 C. `6 y
The remarkable news about Sprycel cessation is that all 3 patients had failed
/ u" L& k1 A8 N8 |3 o, l/ uGleevec and Sprycel was their second TKI so they had resistant disease. This is
0 D8 m+ _& v% W$ _8 _different from the stopping Gleevec trial in France which only targets patients
who have done well on Gleevec.

3 d, q9 R' d/ ?; `/ n$ W2 b. NHopefully, the doctors will report on a larger study and long-term to see if the
- T1 K3 o, h/ e# ]9 h, K- lresponse off Sprycel is sustained.
: [/ v+ R( H  Q- y; o0 v
Best Wishes,
Anjana
! Y' d$ c8 I& ]; r
/ P) g7 d7 }  \$ B
& i/ m! `: U2 Q6 m; ~. e
Haematologica. 2011 Aug 9. [Epub ahead of print]
- |" x/ U) I+ u; [$ m0 Z5 |0 E6 S8 _- IDurable complete molecular remission of chronic myeloid leukemia following
  ~& X/ @9 W! S3 j# Y' q- jdasatinib cessation, despite adverse disease features.
3 q* w7 W% E) I; a# @! N3 p( x  }Ross DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.
' w6 M, s5 R$ c  I6 n* a1 FSource
Adelaide, Australia;

Abstract
! ^3 i5 |0 U5 D5 T. PPatients with chronic myeloid leukemia, treated with imatinib, who have a
! M% Q9 ?2 K& l2 K7 C, t$ ?' `durable complete molecular response might remain in CMR after stopping
treatment. Previous reports of patients stopping treatment in complete molecular
: j6 E9 O3 K' \4 Dresponse have included only patients with a good response to imatinib. We
% U# l1 W# r0 C/ g; Q( F, V# `( `describe three patients with stable complete molecular response on dasatinib
4 O6 }$ v4 z0 ^1 _; _treatment following imatinib failure. Two of the three patients remain in
" j; C: \; B! h) g% C$ e5 Wcomplete molecular response more than 12 months after stopping dasatinib. In
- W& Z, _2 i' L: h6 Cthese two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
$ T) M5 P; V0 U0 i# Xshow that the leukemic clone remains detectable, as we have previously shown in
2 U4 z2 @& `3 G; G5 `imatinib-treated patients. Dasatinib-associated immunological phenomena, such as
the emergence of clonal T cell populations, were observed both in one patient
- ~% _+ f: _3 C" J% w7 swho relapsed and in one patient in remission. Our results suggest that the
0 \* I. }* E# K8 a; L* m* }characteristics of complete molecular response on dasatinib treatment may be
; G$ r+ M6 f' R. h5 {! L9 Psimilar to that achieved with imatinib, at least in patients with adverse
/ Q+ i4 s) c! ~disease features.
" j' B% T5 o% v( _+ V

摘要：（STIM试验为法国的格列卫停药试验。）这个研究中，患者先是取得了CMR（融合基因转阴），然后停用格列卫，而后复发。15名复发患者在重新服药后又一次取得了CMR，他们同意再次停药。
    第一次CMR持续时间为31个月，然后患者停药，复发的中位时间为2.6个月，然后重新服用格列卫，中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后，患者同意再次停药，这次，15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR，而10名患者在停药中位时间2月后第二次复发。
    请注意，这些患者都是在第一次CMR后停药然后又复发的患者。
9 B; A- J3 j9 u- h
作者：来自法国STIM试验
# @5 b' m5 M2 w9 H4 o; F  R来源：EHA 2011.6.会议摘要

很不错的文章，看来马老师家有考虑停药的想法了啊！祝福！

期盼易或特也能停药，但现在觉得是一个梦想！

这个非常有意义的研究。能吃下来停会再吃，再停，那是天大的好事